证券代码：301207 证券简称：华兰疫苗 公告编号：2025-028 华兰生物疫苗股份有限公司 关于开立闲置募集资金现金管理专用结算账户的公告 华兰生物疫苗股份有限公司（以下简称"公司"或"华兰疫苗"）于2025年2月28日 召开了第二届董事会第十二次会议、第二届监事会第十次会议，审议通过了《关于 继续使用部分闲置募集资金进行现金管理的议案》，公司董事会同意在确保不影响 募集资金投资项目建设和公司正常生产经营的前提下，继续使用不超过人民币10亿 元闲置募集资金进行现金管理，现金管理有效期自董事会审议通过之日起12个月内 有效。在上述额度和期限内，资金可循环滚动使用。同时公司董事会授权公司管理 层在额度范围内行使该项投资决策权并签署相关协议及办理相关具体事宜。具体内 容详见公司于2025年3月1日在巨潮资讯网披露的《关于继续使用部分闲置募集资金 进行现金管理的公告》（公告编号：2025-006）。 近日，为更好地进行现金管理，公司开立了闲置募集资金现金管理专用结算账 户，本次开立的账户具体信息如下： | 序号 | 账户名称 | 开户机构 | 账号 | | --- | --- | --- | --- | | 1 ...

Core Viewpoint - Sanofi's quadrivalent influenza vaccine has been approved for the 2025-2026 flu season after a previous suspension due to efficacy concerns in the 2024-2025 season [1][3] Group 1: Sanofi's Vaccine Status - Sanofi decided to suspend the supply and sale of its influenza vaccines in China for the 2024-2025 season due to a decline in efficacy observed during stability assessments [1] - The company has since optimized the immunogenicity and product stability evaluation for the 2025-2026 flu season, completing trial production in December 2024 with stable efficacy results [1] Group 2: Market Dynamics - During Sanofi's suspension, several domestic vaccine manufacturers reduced their prices to capture market share, with the price of quadrivalent vaccines dropping from 128 yuan to 88 yuan per dose [2] - The price of trivalent vaccines has seen even more drastic reductions, with public trivalent vaccines reaching a historical low of 6 yuan per dose [2] - Recent procurement results from Zhejiang Province show competitive pricing among local manufacturers, with successful bids at 6 yuan and 8.8 yuan per dose [2]

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-027 华兰生物疫苗股份有限公司 2024年年度权益分派实施公告 3、本次权益分派实施后除权除息参考价=（除权除息日前一日收盘价-按公司总 股本折算的每股现金红利）=除权除息日前一日收盘价-0.1979942 元/股。 【注：根据相关要求，此项数据保留七位小数，最后一位直接截取，不四舍五 入。】 一、股东大会审议通过利润分配方案情况 1、2025 年 4 月 25 日，华兰生物疫苗股份有限公司（以下简称"公司"）召开 2024 年度股东大会审议通过了《关于 2024 年度利润分配的议案》：公司当前总股本为 601,027,500 股，剔除公司回购专用证券账户中已回购股份 6,027,467 股后为 595,000,033 股，公司以 595,000,033 股为基数向全体股东每 10 股派现金股利 2 元 （含税），共计 119,000,006.60 元；本年度不送红股、不以资本公积转增股本。分配 现金红利后剩余未分配利润 2,175,468,168.32 元滚存至下一年度。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记 ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，华兰生物疫苗股份有限公司（以下简称 "公司"）定于 2025 年 5 月 22 日（周四）15:25-16:55 参加在全景网举办的河南 辖区上市公司 2025 年投资者网上集体接待日活动，本次活动将采用网络远程的 方式举行，投资者可登录"全景·路演天下"（http://rs.p5w.net）参与本次互动交 流。 出席本次网上集体接待日活动的人员有：公司财务总监兼董事会秘书路珂先 生，证券事务代表李伦先生，欢迎广大投资者积极参与。 特此公告。 华兰生物疫苗股份有限公司董事会 证券代码：301207 证券简称：华兰疫苗 公告编号：2025-026 华兰生物疫苗股份有限公司 关于参加河南辖区上市公司 2025年投资者网上集体接待日活动的公告 2025 年 5 月 17 日 ...

Core Viewpoint - The bidding price for influenza vaccines in Shenzhen has reached a historical low, with the winning bid for a trivalent influenza vaccine set at 8 yuan per dose, significantly impacting the competitive landscape of the vaccine market [1][6]. Group 1: Bidding Results - The winning supplier, Fosun Yalifeng, won the bid for 1.6 million doses of the trivalent influenza vaccine at a price of 8 yuan per dose [1][6]. - Other bidders included Changchun Biological Products Institute and Beijing Kexing, with bids of 8.35 yuan and 8.8 yuan per dose, respectively, all below 9 yuan [1][6]. - In comparison, the winning bid for a similar vaccine in Zhejiang province was 9.4 yuan per dose, indicating a regional price disparity [4]. Group 2: Competitive Landscape - The price competition among vaccine manufacturers has intensified, with many players in the market leading to price reductions as a key competitive factor [6][8]. - The scoring criteria for the bidding process included price, technical aspects, business components, integrity, and overall strength, with price accounting for 30% of the total score [6][8]. - The price war has also affected the financial performance of related companies, with significant profit declines reported, such as a 76% drop in net profit for Hualan Biological and a widening loss for Jindike [9].

Core Insights - The vaccine industry is currently facing significant challenges due to suboptimal vaccination rates, leading to decreased revenues for vaccine companies [1][2] - In 2024, out of 14 listed vaccine companies in the A-share market, 12 reported a decline in net profit attributable to shareholders [2] - By the first quarter of 2025, 8 companies continued to experience a decline in net profit, with some companies reporting over an 80% drop [2] Company Performance - Wantai Biological Pharmacy achieved a revenue of 401 million yuan in Q1 2025, a year-on-year decrease of 46.76%, and reported a net loss of 52.78 million yuan [2][3] - Wantai attributed its revenue decline to market adjustments, government procurement policies, and lower-than-expected sales of the nine-valent HPV vaccine [2] - Wantai also recorded impairment losses totaling 51.33 million yuan in Q1 2025, primarily from accounts receivable and inventory [3] Impairment and Credit Losses - Wantai's impairment losses included 45.83 million yuan from accounts receivable and 549,780 yuan from inventory [3] - The increase in accounts receivable impairment was due to delayed payments from local disease control centers, which are affected by tight fiscal conditions [3] - Other companies, such as Zhifei Biological Products, reported a revenue drop of 79.16% in Q1 2025, with a net loss of 305 million yuan [4] Industry Challenges - The primary challenge for vaccine companies is to increase vaccination rates among the population, particularly for self-paid vaccines [5] - Vaccination rates for self-paid vaccines, including flu and HPV vaccines, remain low in China, often in single-digit percentages [5] - There is a need for better communication and education regarding the benefits of vaccination, especially among chronic disease patients [6]

Core Viewpoint - 康希诺 has shown significant improvement in its financial performance, with a notable reduction in losses and a positive revenue growth trajectory, indicating a potential recovery from the impacts of the COVID-19 pandemic [2][3][4]. Financial Performance - In Q1 2025, 康希诺 reported revenue of 1.074 billion yuan, a year-on-year increase of 20.02%, while the net loss attributable to shareholders was 11.55 million yuan, down from a loss of 170 million yuan in the same period last year [2]. - The company achieved a substantial reduction in losses due to several factors, including the absence of one-time special losses from the previous year, increased market share of its meningococcal products, and additional government subsidies [2][4]. - For the full year 2024, 康希诺's revenue grew by 137.01% to 846 million yuan, with a narrowed net loss of 379 million yuan [3]. Market Position and Competitiveness - 康希诺's performance stands out in a challenging vaccine market, where most domestic vaccine manufacturers reported declines in revenue [4][3]. - The company’s meningococcal vaccine, 曼海欣, has become a key revenue driver, contributing significantly to its Q1 2025 revenue [7][10]. - Despite the overall decline in the meningococcal vaccine market, 康希诺's products have shown growth, with 曼海欣's approval and sales expected to continue expanding [9][10]. Product Pipeline and Future Prospects - 康希诺 has two approved meningococcal vaccines, with 曼海欣 being the primary revenue contributor, and is actively pursuing market expansion both domestically and internationally [6][10]. - The company is also awaiting approval for its 13-valent pneumococcal conjugate vaccine, which could further enhance its product portfolio, although competition in this segment is strong [11]. - The future growth potential of 康希诺 remains uncertain, as its current and upcoming products may not provide significant long-term growth opportunities [11].

Core Viewpoint - The performance of several vaccine companies in China is significantly declining in 2024 due to industry policy adjustments, decreased public willingness to vaccinate, and changing market demands, leading to a challenging environment for the industry [1] Financial Performance - The average revenue of vaccine companies in 2024 is 7.131 billion yuan, down 21.63% from 9.099 billion yuan in 2023, while the average net profit is 788 million yuan, a decrease of 35.60% from 1.222 billion yuan in 2023 [1] - Companies like Zhifei Biological, Wantai Biological, and Hualan Biological reported revenue declines exceeding 50%, while Watson Biological, Baike Biological, and Jindike saw declines of over 30% [1] - Kangxino's revenue increased by over 130% due to its quadrivalent meningococcal conjugate vaccine, benefiting from the resolution of global public health events [1] Price Competition Impact - The price war among vaccine products, particularly HPV, influenza, and pneumonia vaccines, has severely impacted net profits, with Wantai Biological, Kangtai Biological, Hualan Biological, and Zhifei Biological experiencing declines of 91.49%, 76.59%, 76.10%, and 74.99% respectively [2] - Wantai Biological's revenue for 2024 is 2.245 billion yuan, down 59.25%, and its net profit is 106 million yuan, down 91.49% [6] - Watson Biological's revenue is 2.821 billion yuan, a decline of 31.41%, with a net profit of 142 million yuan, down 66.10% [6] Market Dynamics - The domestic vaccine market is becoming increasingly competitive, with many companies focusing on traditional products and facing challenges from product homogeneity and market saturation [3] - The overall vaccination rate in China is low, with only about 3% for influenza vaccines, indicating significant growth potential in the market despite current pressures [7] R&D and Innovation - Companies are increasing R&D investments, with Zhifei Biological investing 1.391 billion yuan in 2024, and several companies allocating over 20% of their revenue to R&D [8] - New vaccine technologies, including mRNA and DNA vaccines, are emerging, which could lead to breakthroughs in disease prevention and treatment [9] International Expansion - Many vaccine companies are pursuing international markets, with Kangxino and Baike Biological successfully exporting products to various countries [10][11] - Watson Biological reported overseas revenue of 570 million yuan in 2024, a year-on-year increase of approximately 98% [11] - The global human vaccine market is projected to grow significantly, with emerging markets providing opportunities for Chinese vaccine companies due to their competitive pricing [12][13]

Core Viewpoint - The company, Hualan Biological Engineering Inc., has released its first quarter report for 2025, ensuring the accuracy and completeness of the financial information disclosed, with no significant omissions or misleading statements [1][2]. Financial Data Summary - The first quarter report has not been audited [3][7]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - Non-recurring gains and losses include a refund of handling fees [3]. - The company confirms that there are no instances of classifying non-recurring gains and losses as recurring [3]. Shareholder Information - As of the reporting period, the total number of ordinary shareholders is not disclosed, but the company holds 6,027,467 shares in a repurchase account, representing 1.00% of total shares, ranking fifth among the top ten shareholders [5].

Group 1: Company Performance - In Q1, Hualan Biological achieved revenue of 868 million yuan, a year-on-year increase of 10.2% [1] - The net profit attributable to shareholders was 313 million yuan, up 19.62% year-on-year, while the net profit excluding non-recurring gains and losses was 300 million yuan, increasing by 35.35% [1] - The blood products segment generated revenue of 843 million yuan, with a year-on-year growth of 11.98% and a net profit of 291 million yuan, reflecting a 23.47% increase [1] Group 2: Vaccine Business - Hualan Vaccine reported Q1 revenue of 24.28 million yuan, a decline of 29.05% year-on-year, with a net profit of 32.78 million yuan, down 15.06% [2] - The net profit excluding non-recurring gains and losses was 15.42 million yuan, showing an increase of 8.89% [2] - The company anticipates that vaccine sales will improve in Q2 as product approvals and sales efforts ramp up [2] Group 3: Industry Trends - The plasma collection volume for Hualan Biological reached a record high of 1586.37 tons in 2024, marking an 18.18% increase [3] - The blood products industry is experiencing increased merger and acquisition activities, with plasma stations becoming a strategic focus for companies [3] - Notable acquisitions include Boya Biological's purchase of 100% of Green Cross China for 1.82 billion yuan, adding 4 plasma stations, and Tian Tan Biological's acquisition of 5 plasma stations from CSL Asia Pacific [3]